BR112021024897A2 - Métodos de produção de um anticorpo anti-a4ss7 - Google Patents
Métodos de produção de um anticorpo anti-a4ss7Info
- Publication number
- BR112021024897A2 BR112021024897A2 BR112021024897A BR112021024897A BR112021024897A2 BR 112021024897 A2 BR112021024897 A2 BR 112021024897A2 BR 112021024897 A BR112021024897 A BR 112021024897A BR 112021024897 A BR112021024897 A BR 112021024897A BR 112021024897 A2 BR112021024897 A2 BR 112021024897A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- methods
- producing
- a4ss7
- vedolizumab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
métodos de produção de um anticorpo anti-alfa4beta7. a presente invenção refere-se a métodos para purificar um anticorpo anti-a4ß7 integrina, como vedolizumabe, a partir de uma solução líquida, por exemplo, de uma colheita clarificada de cultura de células de mamíferos. a invenção refere-se, inter alia, a métodos de purificação para controlar a quantidade de substâncias relacionadas ao produto e / ou impurezas relacionadas ao processo presentes em preparações purificadas de um anticorpo anti-a4ß7 integrina, ou fragmento de ligação ao antígeno do mesmo, por exemplo, vedolizumabe. composições que compreendem um anticorpo anti-a4ß7, e usos dos mesmos para tratar um distúrbio, também são fornecidas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859494P | 2019-06-10 | 2019-06-10 | |
| PCT/US2020/037059 WO2020252069A1 (en) | 2019-06-10 | 2020-06-10 | METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024897A2 true BR112021024897A2 (pt) | 2022-01-18 |
Family
ID=73781728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024897A BR112021024897A2 (pt) | 2019-06-10 | 2020-06-10 | Métodos de produção de um anticorpo anti-a4ss7 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220267449A1 (pt) |
| EP (1) | EP3980466A4 (pt) |
| JP (1) | JP2022536486A (pt) |
| CN (1) | CN114375307A (pt) |
| AR (1) | AR119270A1 (pt) |
| AU (1) | AU2020290943A1 (pt) |
| BR (1) | BR112021024897A2 (pt) |
| CA (1) | CA3143167A1 (pt) |
| IL (1) | IL288825A (pt) |
| MA (1) | MA56129A (pt) |
| MX (1) | MX2021015300A (pt) |
| PL (1) | PL439809A1 (pt) |
| TW (1) | TW202112818A (pt) |
| WO (1) | WO2020252069A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112243379A (zh) * | 2018-04-10 | 2021-01-19 | 雷迪博士实验室有限公司 | 稳定的抗体制剂 |
| WO2023007516A1 (en) * | 2021-07-29 | 2023-02-02 | Dr. Reddy’S Laboratories Limited | Method to control high molecular weight aggregates in an antibody composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2014142882A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Protein purification using displacement chromatography |
| MA41636A (fr) * | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
-
2020
- 2020-06-10 JP JP2021573298A patent/JP2022536486A/ja active Pending
- 2020-06-10 WO PCT/US2020/037059 patent/WO2020252069A1/en unknown
- 2020-06-10 CN CN202080049572.2A patent/CN114375307A/zh active Pending
- 2020-06-10 AU AU2020290943A patent/AU2020290943A1/en active Pending
- 2020-06-10 TW TW109119563A patent/TW202112818A/zh unknown
- 2020-06-10 MX MX2021015300A patent/MX2021015300A/es unknown
- 2020-06-10 CA CA3143167A patent/CA3143167A1/en active Pending
- 2020-06-10 MA MA056129A patent/MA56129A/fr unknown
- 2020-06-10 PL PL439809A patent/PL439809A1/pl unknown
- 2020-06-10 US US17/596,421 patent/US20220267449A1/en active Pending
- 2020-06-10 AR ARP200101641A patent/AR119270A1/es unknown
- 2020-06-10 EP EP20822340.4A patent/EP3980466A4/en active Pending
- 2020-06-10 BR BR112021024897A patent/BR112021024897A2/pt unknown
-
2021
- 2021-12-09 IL IL288825A patent/IL288825A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR119270A1 (es) | 2021-12-09 |
| EP3980466A4 (en) | 2023-06-07 |
| JP2022536486A (ja) | 2022-08-17 |
| MA56129A (fr) | 2022-04-13 |
| CA3143167A1 (en) | 2020-12-17 |
| MX2021015300A (es) | 2022-02-03 |
| EP3980466A1 (en) | 2022-04-13 |
| IL288825A (en) | 2022-02-01 |
| US20220267449A1 (en) | 2022-08-25 |
| WO2020252069A1 (en) | 2020-12-17 |
| PL439809A1 (pl) | 2022-12-05 |
| AU2020290943A1 (en) | 2022-02-03 |
| TW202112818A (zh) | 2021-04-01 |
| CN114375307A (zh) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Levi et al. | CD105 protein depletion enhances human adipose-derived stromal cell osteogenesis through reduction of transforming growth factor β1 (TGF-β1) signaling | |
| RU2768003C2 (ru) | Интегрированное непрерывное производство терапевтических белковых лекарственных веществ | |
| BR112021024897A2 (pt) | Métodos de produção de um anticorpo anti-a4ss7 | |
| CO6640239A2 (es) | Proceso par preparar una composición de inmunoglobulina | |
| EP4349854A3 (en) | Pd1-cd28 fusion proteins and their use in medicine | |
| BR112017023912A2 (pt) | sistema modular e processo para produção contínua e/ou processamento de um produto de forma desinfectada | |
| BR112015009553A2 (pt) | Método para separar uma proteína de interesse de uma solução de cultura de células | |
| BR112015010360A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que pode se ligar especificamente ao sítio ii de uma il-6 humana, seus usos, ácido nucleico, composição, vetor, célula, e processo para produzir a mesma | |
| BRPI1012321A8 (pt) | Anticorpos anti-vegf e seus usos | |
| PH12020500027A1 (en) | Purification of iduronate-2-sulfatase | |
| SG157346A1 (en) | Improved purification of collagenases from clostridium histolyticum liquid culture | |
| BR112021024848A2 (pt) | Métodos de purificação de anticorpos e composições dos mesmos | |
| BR112015012854A2 (pt) | método para purificar proteínas terapêuticas | |
| BR112015012538A2 (pt) | anticorpos anti-vegf e seus usos | |
| BR112018069283A2 (pt) | anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos | |
| EA201491564A1 (ru) | Осаждение фракции i-iv-1 иммуноглобулинов из плазмы | |
| AR091155A1 (es) | Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion | |
| Schiera et al. | Extracellular vesicles shed by melanoma cells contain a modified form of H1. 0 linker histone and H1. 0 mRNA-binding proteins | |
| BR112022002831A2 (pt) | Formulações anti-c5 de alta concentração | |
| BR112014020685A2 (pt) | planta transgênica resistente a patógenos | |
| ATE522263T1 (de) | Verfahren zur reinigung von ionischen flüssigkeiten | |
| EA201000769A1 (ru) | Катенированные молекулы и содержащие их композиции для иммуностимуляции | |
| BR112015021883A8 (pt) | métodos para controle da concentração de microrganismos indesejáveis em uma solução aquosa empregada em um processo de fermentação | |
| BR112014027994A2 (pt) | métodos de cristalização para purificação de anticorpos monoclonais | |
| EA201500185A1 (ru) | Композиция, содержащая нуклеиновые кислоты паразитических, патогенных или инвазивных биологических систем для ингибирования и/или контроля роста указанных систем, и способ ее получения |